Jinlida for Diabetes Prevention in Impaired Glucose Tolerance and Multiple Metabolic Abnormalities: The FOCUS Randomized Clinical Trial
Hangyu Ji,Xuefei Zhao,Xinyan Chen,Hui Fang,Huailin Gao,Geng Wei,Min Zhang,Hongyu Kuang,Baijing Yang,Xiaojun Cai,Yanjin Su,Chunli Piao,Shuyu Zhao,Liyang Li,Wenliang Sun,Tianshu Xu,Qinghua Xu,Yuan Fan,Jianhua Ye,Chen Yao,Meixia Shang,Guangyao Song,Liming Chen,Qingshan Zheng,Xinhua Xiao,Li Yan,Fengmei Lian,Xiaolin Tong,Zhenhua Jia,FOCUS Trial Committees and Investigators,Liying Lun,Sulin Hu,Haipeng Liu,Guangyu Cai,Huan Li,Ling Huang,Mengling Tian,Jiale Wan,Peizhen Song,Yaqin Zhang,Fan Li,Xiaoyan Hu,Jing Xu,Ying Pang,Jing Shi,Hongwei Cheng,Wenhong Tian,Huiling Wang,Gangxin Qin,Qiuju Zhao,Lulu Wang,Junting Luo,Luyv Liu,Li Zhao,Wenjiao Xie,Xinlun Cai,Gaohong Qiao,Aoran Song,Jianxiu Li,Wendan Zhang,Qiong Wu,Yanan Wang,Qijun Fang,Lijun Yue,Yuling Zhang,Li Hu,Qin You,Li Wang,Siyu Zhao,Liwei Zhang,Hui Guo,Lina Dai,Wenjuan Niu,Wei Gao,Minzhou Li,Ruixia Zhang,Yixuan Liu,Jingwen Wang,Congchao Zhang,Siyuan Li,Yurong Feng,Yingran Dai,Ren Sa,Lili Sang,Haiyan Wang,Weiwei Yin,Hong Zhang,Fengjun Sun,Li Ma,Junyong Yang,Xuanmin Zhang,Xia Gan,Yang Sheng,Yun Zhou,Junhu Lu,Tong Xu,Haoran Li,Zhen Li,Xiaoxia Pan,Li Zhang,Jialin Han,Acui Yu,Jingqing Jing,Li Huang,Xi Chen,Xuling Wang,Jilai Shi,Bingyan Wang,Guanghui Sun,Kaimin Li,Tingting Zhou,Mengying Shi,Hongli Liu,Xueling Sun,Hewei Zhang,Wenhui Hong,Nan Huang,Xiufen Chen,Jinxiang Zheng,Yongjuan Juan,Rongrong Zhou,Huidan Wang,Chunxue Zang,Yiwen Lai,Zedong Peng,Ruyu Chen,Xinhui Liu,Mengjie Cai,Xu Han
DOI: https://doi.org/10.1001/jamainternmed.2024.1190
2024-07-01
Abstract:Importance: Previous studies have shown that Jinlida (JLD) granules, an approved treatment for type 2 diabetes in China, can reduce blood glucose level, reduce glycated hemoglobin (HbA1c), and improve insulin resistance in people with type 2 diabetes. Objective: To evaluate the effect of long-term administration of JLD vs placebo on the incidence of diabetes in participants with impaired glucose tolerance (IGT) and multiple metabolic abnormalities. Design, setting, and participants: This multicenter, double-blind, placebo-controlled randomized clinical trial (FOCUS) was conducted across 35 centers in 21 cities in China from June 2019 to February 2023. Individuals aged 18 to 70 years with IGT and multiple metabolic abnormalities were enrolled. Intervention: Participants were randomly allocated 1:1 to receive JLD or placebo (9 g, 3 times per day, orally). They continued this regimen until they developed diabetes, withdrew from the study, were lost to follow-up, or died. Main outcomes and measures: The primary outcome was the occurrence of diabetes, which was determined by 2 consecutive oral glucose tolerance tests. Secondary outcomes included waist circumference; fasting and 2-hour postprandial plasma glucose levels; HbA1c; fasting insulin level; homeostatic model assessment for insulin resistance (HOMA-IR); total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels; ankle-brachial index; and carotid intima-media thickness. Results: A total of 889 participants were randomized, of whom 885 were in the full analysis set (442 in the JLD group; 443 in the placebo group; mean [SD] age, 52.57 [10.33] years; 463 [52.32%] female). Following a median observation period of 2.20 years (IQR, 1.27-2.64 years), participants in the JLD group had a lower risk of developing diabetes compared with those in the placebo group (hazard ratio, 0.59; 95% CI, 0.46-0.74; P < .001). During the follow-up period, the JLD group had a between-group difference of 0.95 cm (95% CI, 0.36-1.55 cm) in waist circumference, 9.2 mg/dL (95% CI, 5.4-13.0 mg/dL) in 2-hour postprandial blood glucose level, 3.8 mg/dL (95% CI, 2.2-5.6 mg/dL) in fasting blood glucose level, 0.20% (95% CI, 0.13%-0.27%) in HbA1c, 6.6 mg/dL (95% CI, 1.9-11.2) in total cholesterol level, 4.3 mg/dL (95% CI, 0.8-7.7 mg/dL) in low-density lipoprotein cholesterol level, 25.7 mg/dL (95% CI, 15.9-35.4 mg/dL) in triglyceride levels, and 0.47 (95% CI, 0.12-0.83) in HOMA-IR compared with the placebo group. After 24 months of follow-up, the JLD group had a significant improvement in ankle-brachial index and waist circumference compared with the placebo group. Conclusions and relevance: The findings suggest that JLD can reduce the risk of diabetes in participants with IGT and multiple metabolic abnormalities. Trial registration: Chinese Clinical Trial Register: ChiCTR1900023241.